Inotek Pharmaceuticals also has a robust preclinical pipeline of poly (ADP ribose) polymerase (PARP) inhibitors and superoxide dismutase mimetic (SODm) compounds that the Company believes hold significant potential in retinal disease, including diabetic retinopathy and age-related macular degeneration.